← board
BBOT
distress 3/10 · well-funded / low risk$8.66-3%today-37% from 52w high
Lead: NSCLC
Revenue
pre-revenue
Liquidity
$389M
Runway
3.6 yrs
Shares 1y
+0%
Price & events
-23.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.7%
1D
+4.2%
1W
+15.5%
1M
-3.5%
3M
-31.4%
6M
-19.0%
1Y
-16.0%
2Y
—
5Y
-15.0%
All
Overview
- Market Cap
- $693.73M
- Volume
- 4.08K
- 52 Week Range
- $7.12 – $13.73
- Total Shares
- 80.11M
- Float Shares
- 35.74M
- Short %
- 18.30%
- % Held by Insiders
- 27.11%
- % Held by Institutions
- 68.90%
- RVOL
- 0.01x
- Beta
- 0.39
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- this yearGuided 40%trial initiationsecondaryBBO-8520 and BBO-11818 · Internal combination studies anticipated to openSEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- second half of 2026readoutPhase 1/2BBO-8520 · Additional pembrolizumab combination efficacy and safety dataSEC 8-K
- 2025-08-11partnershipBusiness combination with Helix Acquisition Corp. IISEC 8-K
- 2025-02-28partnershipexecuted business combination agreementSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $25 (+192% upside) · 10 analysts
- 2026-07-08JP MorganOverweight
- 2026-05-11Canaccord GenuityBuy
- 2026-03-06HC Wainwright & Co.Buy
- 2026-02-11StifelBuy
- 2026-01-09Raymond JamesOutperform
- 2025-12-11WedbushOutperform
Competitors — NSCLC
- PFEPFIZER INC$142.2B · D3
- RVMDRevolution Medicines, Inc.$40.3B · D1
- IDYAIDEAYA Biosciences, Inc.$3.0B · D3
- AVBPArriVent BioPharma, Inc.$1.4B · D1
- ORICOric Pharmaceuticals, Inc.$1.1B · D3
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- VSTMVerastem, Inc.$515M · D5
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- BDTXBlack Diamond Therapeutics, Inc.$104M · D5
- NUVLNuvalent, Inc.— · D1
Recent news
- 2026-07-13BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment - Seeking Alpha
- 2026-07-11BBOT Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Inspire Confidence as Shares Slide - DonanımHaber
- 2026-07-10BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 7.9% - Should You Sell? - MarketBeat
- 2026-07-08BBOT Initiated Coverage by JP Morgan -- Rating Set to Overweight - GuruFocus
- 2026-07-08JPMorgan initiates BridgeBio Oncology stock with overweight rating - Investing.com
- 2026-07-03BBOT SEC Filings - BridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
- 2026-06-30Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? - Yahoo Finance
- 2026-06-25BBOT Forecast — Price Target — Prediction for 2027 - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.